PURPOSE: Our aim was to investigate the macular response to three different supplements containing lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ) in normal subjects and those with age-related macular degeneration (AMD). MATERIALS AND METHODS:Macular pigment optical density (MPOD) and serum xanthophyll concentrations were measured in normal (n = 31) and AMD subjects (n = 32), randomly assigned to: group 1 (20 mg L, 2 mg Z, 0.3 mg MZ), group 2 (10 mg L, 2 mg Z, 10 mg MZ) or group 3 (3 mg L, 2 mg Z, 17 mg MZ). MPOD was measured at baseline, 2, 4, 6 and 8 weeks and at 0.25°, 0.5°, 1.0° and 1.75° of eccentricity using customised heterochromatic flicker photometry and serum xanthophylls by HPLC. RESULTS:MPOD increased significantly at all eccentricities in each group (p < 0.05), except at 1.75° in group 3 (p = 0.242). There was no difference in MPOD measurements between AMD and normal subjects, except for group 2, where AMD subjects exhibited a greater response at 1.75° (p = 0.012). Final serum concentrations of MZ were positively and significantly related to final MPOD values at each eccentricity in all subjects. Targeted analysis of those subjects receiving the MZ-containing supplements exhibited stronger relationships between serum MZ concentrations and MPOD at 0.25° in group 3 than group 2; in group 2 all associations were positive, but only significant at 1.75°. CONCLUSIONS:Serum concentrations of MZ were strongly correlated with MPOD after 8 weeks of supplementation with the group 3 formulation, but the inclusion of L in the group 2 formulation may result in greater MPOD augmentation across the spatial profile.
RCT Entities:
PURPOSE: Our aim was to investigate the macular response to three different supplements containing lutein (L), zeaxanthin (Z) and meso-zeaxanthin (MZ) in normal subjects and those with age-related macular degeneration (AMD). MATERIALS AND METHODS: Macular pigment optical density (MPOD) and serum xanthophyll concentrations were measured in normal (n = 31) and AMD subjects (n = 32), randomly assigned to: group 1 (20 mg L, 2 mg Z, 0.3 mg MZ), group 2 (10 mg L, 2 mg Z, 10 mg MZ) or group 3 (3 mg L, 2 mg Z, 17 mg MZ). MPOD was measured at baseline, 2, 4, 6 and 8 weeks and at 0.25°, 0.5°, 1.0° and 1.75° of eccentricity using customised heterochromatic flicker photometry and serum xanthophylls by HPLC. RESULTS: MPOD increased significantly at all eccentricities in each group (p < 0.05), except at 1.75° in group 3 (p = 0.242). There was no difference in MPOD measurements between AMD and normal subjects, except for group 2, where AMD subjects exhibited a greater response at 1.75° (p = 0.012). Final serum concentrations of MZ were positively and significantly related to final MPOD values at each eccentricity in all subjects. Targeted analysis of those subjects receiving the MZ-containing supplements exhibited stronger relationships between serum MZ concentrations and MPOD at 0.25° in group 3 than group 2; in group 2 all associations were positive, but only significant at 1.75°. CONCLUSIONS: Serum concentrations of MZ were strongly correlated with MPOD after 8 weeks of supplementation with the group 3 formulation, but the inclusion of L in the group 2 formulation may result in greater MPOD augmentation across the spatial profile.
Authors: Eithne E Connolly; Stephen Beatty; David I Thurnham; James Loughman; Alan N Howard; Jim Stack; John M Nolan Journal: Curr Eye Res Date: 2010-04 Impact factor: 2.424
Authors: Wolfgang Schalch; William Cohn; Felix M Barker; Wolfgang Köpcke; John Mellerio; Alan C Bird; Anthony G Robson; Fred F Fitzke; Frederik J G M van Kuijk Journal: Arch Biochem Biophys Date: 2006-11-07 Impact factor: 4.013
Authors: Stephen Beatty; Usha Chakravarthy; John M Nolan; Katherine A Muldrew; Jayne V Woodside; Frances Denny; Michael R Stevenson Journal: Ophthalmology Date: 2012-12-06 Impact factor: 12.079
Authors: R Moran; J M Nolan; J Stack; A M O'Halloran; J Feeney; K O Akuffo; R A Kenny; S Beatty Journal: J Nutr Health Aging Date: 2017 Impact factor: 4.075
Authors: Paul S Bernstein; Binxing Li; Preejith P Vachali; Aruna Gorusupudi; Rajalekshmy Shyam; Bradley S Henriksen; John M Nolan Journal: Prog Retin Eye Res Date: 2015-11-02 Impact factor: 21.198
Authors: David Kelly; Robert F Coen; Kwadwo Owusu Akuffo; Stephen Beatty; Jessica Dennison; Rachel Moran; Jim Stack; Alan N Howard; Riona Mulcahy; John M Nolan Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: Sanne M van der Made; Elton R Kelly; Aize Kijlstra; Jogchum Plat; Tos T J M Berendschot Journal: J Ophthalmol Date: 2016-03-14 Impact factor: 1.909